Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lefukang is a Traditional Chinese Medicine (TCM) capsule developed by Chongqing Searainbow Pharmaceutical for the treatment of chronic pelvic pain resulting from pelvic inflammatory disease (PID). It is specifically indicated for patients presenting with 'Qi stagnation and blood stasis syndrome,' a TCM diagnostic category characterized by persistent lower abdominal pain, distension, and tenderness. The formulation consists of multiple botanical extracts intended to promote blood circulation, resolve stasis, and alleviate pain. Clinical development in China has focused on establishing its efficacy and safety for drug registration as a treatment for the sequelae of PID, with Phase 3 trials conducted to support its regulatory approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lefukang (Chongqing Searainbow Pharmaceutical).